564 related articles for article (PubMed ID: 29945939)
1. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
2. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
4. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
6. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
7. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Kernan NA; Grupp S; Smith AR; Arai S; Triplett B; Antin JH; Lehmann L; Shore T; Ho VT; Bunin N; Iacobelli M; Liang W; Hume R; Tappe W; Soiffer R; Richardson P
Br J Haematol; 2018 Jun; 181(6):816-827. PubMed ID: 29767845
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.
Richardson PG; Riches ML; Kernan NA; Brochstein JA; Mineishi S; Termuhlen AM; Arai S; Grupp SA; Guinan EC; Martin PL; Steinbach G; Krishnan A; Nemecek ER; Giralt S; Rodriguez T; Duerst R; Doyle J; Antin JH; Smith A; Lehmann L; Champlin R; Gillio A; Bajwa R; D'Agostino RB; Massaro J; Warren D; Miloslavsky M; Hume RL; Iacobelli M; Nejadnik B; Hannah AL; Soiffer RJ
Blood; 2016 Mar; 127(13):1656-65. PubMed ID: 26825712
[TBL] [Abstract][Full Text] [Related]
9. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Ho VT; Revta C; Richardson PG
Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
[TBL] [Abstract][Full Text] [Related]
10. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
14. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
Nauffal M; Kim HT; Richardson PG; Soiffer RJ; Antin JH; Cutler C; Nikiforow S; Gooptu M; Koreth J; Romee R; Ho VT
Blood Adv; 2022 Jan; 6(1):181-188. PubMed ID: 34666352
[TBL] [Abstract][Full Text] [Related]
15. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
16. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.
Veenstra DL; Guzauskas GF; Villa KF; Boudreau DM
J Med Econ; 2017 May; 20(5):453-463. PubMed ID: 28008770
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.
Carcedo Rodriguez D; Artola Urain T; Chinea Rodriguez A; García Torres E; González Vicent M; Gutiérrez García G; Regueiro García A; Calvo Hidalgo M; Villacampa A
J Med Econ; 2021; 24(1):628-636. PubMed ID: 33858278
[TBL] [Abstract][Full Text] [Related]
18. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
Keating GM
Clin Drug Investig; 2014 Dec; 34(12):895-904. PubMed ID: 25351934
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation.
Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A
Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, multinational, prospective, observational registry study of defibrotide in patients diagnosed with veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic cell transplantation: an EBMT study.
Mohty M; Battista ML; Blaise D; Calore E; Cesaro S; Maximova N; Perruccio K; Renard C; Wynn R; Zecca M; Labopin M; Hanvesakul R; Amber V; Ryan RJ; Lawson S; Ciceri F
Bone Marrow Transplant; 2021 Oct; 56(10):2454-2463. PubMed ID: 34059801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
